Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Setmelanotide Indication In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm's lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm's headquarters is in Boston, MA.
The fireside chats will be webcasted and available under 'Events & Presentations' in the Investor Relations section of the Company's website at www.rhythmtx.com, and webcast replays will be available for 30 days following the presentations.
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences:
Story Continues
In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.
Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.
Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including 'gasping syndrome' can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.
USE IN SPECIFIC POPULATIONS
Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full Prescribing Information for additional Important Safety Information.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication, our participation in upcoming events and presentations, and the date, time and content thereof and the timing of any of the foregoing. Statements using words such as 'expect', 'anticipate', 'believe', 'may', 'will' and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Tom's Guide
a day ago
- Tom's Guide
I take magnesium for sleep, but can a varied diet deliver the same results? I asked three experts
I started taking magnesium glycinate when I was in the throes of insomnia. I wasn't in the right headspace for loading up my plate with magnesium rich foods back then, so supplements filled the gap. Taking magnesium has since become part of my nighttime routine – a deeply ingrained habit. But after recently adding more healthy foods to my diet I'm thinking of ditching my magnesium glycinate supplement altogether. I spoke to three registered dieticians to gain a better understanding of magnesium supplements versus magnesium rich foods for sleep. Here's what they told me… Magnesium is a vital mineral that plays a key role in helping you to relax, in addition to regulating your circadian rhythm (sleep-wake cycle). As Dr Leah Kaylor, Ph.D. MSCP explains: 'Magnesium supports sleep by regulating melatonin and enhancing GABA (calming neurotransmitter). 'Magnesium can influence inflammation and cortisol, both of which can disrupt sleep.' So magnesium is important for sleep (and endless other functions), but how much does the average person need? According to the NIH Office of Dietary Supplements, men need around 400-420mg of magnesium a day, and women need 310-350mg a day. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. However there are other factors to consider, says Elizabeth Huggins, Registered Dietician at Hilton Head Health Wellness Resort and Spa: 'The ideal daily intake depends on your age, sex, and health conditions, including pregnancy.' 'Supplement only when clinically indicated,' advises Dr Kaylor. I've been doing a lot of research into magnesium rich foods as I prepare to ditch my supplement, and the good news is there are lots of options to pick from. 'Nuts, specifically almonds, cashews and peanuts, chia seeds and pumpkin seeds are high in magnesium.' Explains Huggins, RDN. Individuals can meet their magnesium needs by consuming magnesium rich foods daily and using dietary supplements to fill dietary gaps 'Other great choices for a source of magnesium include leafy greens, whole grains, legumes and beans. Certain fatty fish such as salmon or halibut also contain magnesium.' 'It is possible to meet magnesium needs through diet; however, many people don't get the recommended amount.' Dr Kaylor adds. As for me, I've been adding more pumpkin seeds and black beans to my diet (I've always eaten spinach and almonds). 'Individuals can meet their magnesium needs by consuming magnesium-rich foods daily and by using dietary supplements to fill dietary gaps.' Says Holiday Durham, PhD, MS, Registered Dietitian at Amway. Here's a breakdown of how much magnesium is in each of the most popular recommended foods, according to the USDA's FoodCentral Database: I've been supplementing my diet with magnesium glycinate, and this is the one experts seem to favour too. 'Evidence suggests that magnesium glycinate is one form of magnesium that the body may more readily absorb,' Holiday Durham, RD, tells me. Dr Kaylor agrees: 'Magnesium glycinate is the least likely of the magnesium family to cause GI distress.' According to registered dietician Huggins, GI distress can include, 'nausea, diarrhea and abdominal cramping. Magnesium supplements also have the potential to interfere with medications (including cholesterol lowering statins.) There is also a risk in people that have kidney disease.' If you do supplement, don't expect an immediate effect. I only noticed a difference in my sleep after a couple of weeks of taking magnesium glycinate. 'Its effects tend to be gradual, typically becoming noticeable after one to two weeks of consistent intake.' Explains Dr Kaylor. 'In the Abbasi et al. trial, improvements in sleep were seen after eight weeks of daily intake.' Personally, I have found success with taking a regular magnesium glycinate supplement when I've had trouble sleeping in the past. But around the time I started taking it I was also practising better sleep hygiene, one of the most powerful tools I learned for easing insomnia. 'As a sleep expert, magnesium can be a small part of a much larger plan to develop better sleep habits,' agrees Dr Kaylor. '[Magnesium] is not a magic bullet. Its effects are typically modest at best. 'Instead people should focus on a solid wind down routine, consistency in sleep/wake times, and stress management.' Elizabeth Huggins, RDN, also recommends focusing on the whole picture: 'There are a number of factors that influence sleep quality so it's important to take a holistic approach. 'A balanced diet that includes foods with adequate amounts of magnesium are part of the approach to help promote better sleep. 'Some studies have found that magnesium intake can help us sleep better, but there are contradictory findings. Ultimately, more research is needed to learn more about the interaction of how and who it might help.'


Forbes
2 days ago
- Forbes
Breast Milk Bank Helps Babies Thrive In Nepal
Hundreds of newborns receive the nourishment they need to survive and thrive through a program in Kathmandu supported by UNICEF, the government of Nepal and other partners. But plans to expand the services and reach more babies in need are on hold due to funding cuts. New mother Sarita Khatri Tamang rests with her newborn baby in the Kangaroo Mother Care ward at the UNICEF-supported Paropakar Maternity and Women's Hospital in Kathmandu. © UNICEF/UNI792286/Upadhayay New mother Sarita Khatri Tamang holds her baby close as she lies in a bed recovering from a C-section delivery at Paropakar Maternity and Women's Hospital in Kathmandu. She has been unable to breastfeed, but her baby is not missing out on the breast milk needed for optimal infant nutrition. Thanks to the hospital's Amrit Kosh — Nepal's first human milk bank — she is able to receive breast milk donated by other mothers. "At a time when I could barely stand up because I was in so much pain," Tamang says, "it was such a big support for me." The milk bank is part of a comprehensive lactation management center established in 2022 by the government of Nepal, with support from the European Union and UNICEF. The center ensures proper nourishment for newborns in critical condition, including many born prematurely. Around 500 babies are supported every month with donated breast milk — the next best thing to a mother's own milk. Plans to open or expand similar lactation management units in hospitals across Nepal, particularly in facilities serving large numbers of at-risk newborns, have been put on hold due as recent funding cuts have affected UNICEF's ability to support these initiatives. Funding cuts have also disrupted other key UNICEF-supported services including breastfeeding support and counseling. "The demand is still much higher than what the bank can currently supply on a daily basis," says Dr. Kalpana Upadhyaya Subedi, Chief Consultant Pediatrician and head of the Department of Neonatology at Paropakar. 'Expanding such facilities across the country would ensure that more mothers and babies receive the support they need, reducing neonatal mortality and promoting healthier outcomes for future generations." Breastfeeding is the best form of nutrition for babies, especially for the first six months of life. But breast milk is more than a meal. It also plays a critical role in protecting vulnerable infants from infections and malnutrition. On May 2, 2025, Dr. Smriti Poudel counsels new mother Sarita Khatri Tamang at the Paropakar Maternity and Women's Hospital in Kathmandu, where UNICEF supports Nepal's first Human Milk Bank. Expansion plans are on hold due to funding cuts. © UNICEF/UNI792463/Rabik Upadha Nepal faces significant challenges in early childhood nutrition. One in 4 children under age 5 is stunted, and 8 percent are wasted, with limited access to treatment, according to UNICEF. Nearly half of all infants are not exclusively breastfed, and over 1 million children suffer from anemia. 'It makes me happy to think that because of me, lives were saved.' Sushila Nagarkoti is one of the mothers who has donated to the Kathmandu milk bank. "The nurse told me that I was producing a lot of milk and asked if I wanted to donate some; I said okay, since I had more than enough milk for my own child," Nagarkoti says. "It makes me happy to think that because of me, lives were saved." Learn more about UNICEF programs in Asia Your contribution to UNICEF is more important than ever. Please donate. Right now, the lives of the most vulnerable children hang in the balance as conflicts and crises jeopardize the care and protection that they deserve. Dependable, uninterrupted and effective foreign aid is critical to the well-being of millions of children. Please contact your members of Congress and urge them to support ongoing U.S. investments in foreign assistance.


Axios
3 days ago
- Axios
The White House adviser who fueled the Trump-Musk NASA feud
Shortly after President Trump unexpectedly withdrew Elon Musk 's pick to lead NASA last weekend, one name quickly surfaced as a major force behind the surprise decision: top White House aide Sergio Gor. Why it matters: Trump acknowledged Thursday that canceling Jared Isaacman 's NASA nomination had "upset" Musk, who's close to Isaacman. It was a factor, among many, that led to Thursday's shocking falling out between the president and his one-time "First Buddy," the world's richest person. Musk spent the afternoon flaming Trump on X. It left presidential advisers stunned — and some of them angry at Gor, whose tense relationship with Musk was a backdrop to the controversy. Senate Republicans also blamed Gor for helping undermine the NASA nomination to settle a score with Musk, who had been critical of Gor's management of the White House personnel office. Gor declined to comment. But one senior White House official called Axios on Gor's behalf to praise his "brilliance, hard work and dedication." Zoom in: Gor is one of the most influential Trump advisers in the White House, and co-founded Winning Team Publishing with Donald Trump Jr. The imprint publishes books by Trump and his allies, and put much-needed cash in Trump's pocket during his isolation after the Jan. 6 riot at the Capitol. Gor, a frequent presence at Mar-a-Lago, has a close relationship with former Marvel executive Ike Perlmutter, one of Trump's closest friends and a major donor. Gor was a top fundraising official on Trump's 2020 re-election campaign, and founded a pro-Trump super PAC during the 2024 campaign that spent nearly $72 million. Zoom out: As the man in charge of vetting political appointees, Gor implemented loyalty tests to make sure new hires support Trump's agenda wholeheartedly — and that they haven't given to Democrats. Of all of Trump's picks, Isaacman — a wealthy entrepreneur — stood out for having contributed to Democrats during the last election cycle. Trump cited that Saturday when he withdrew Isaacman's nomination. Trump, however, had been made aware of Isaacman's donations months ago and said nothing. Now, the nation's space agency won't have a chief confirmed by the Senate for at least nine months, officials say. Flashback: Musk and Gor had a tense relationship that surfaced in March during a heated Cabinet meeting in which Musk got into an argument with Secretary of State Marco Rubio, The New York Times reported at the time. Gor wasn't mentioned in the Times story, a conspicuous absence in the eyes of two senior administration officials who say Gor resented Musk's involvement in personnel matters. "Sergio let it be known he didn't like Musk's attitude ... and he didn't like getting called out [by Musk] in front of the Cabinet," said one White House official who attended the meeting. The intrigue: In a Wednesday discussion on the "All-In Podcast," Isaacman said he believes his fate was linked to Musk's deteriorating standing in the White House and "an influential adviser coming in and saying [to Trump]: 'Look, here's the facts and I think we should kill this guy.''' "It's crazy," a Trump adviser involved in the NASA director process said. "Isaacman is eminently qualified. He's a billionaire. He has been to space. He was a Democrat — exactly the type of voter we want. And now look at it." Gor has told others he wasn't responsible — and that GOP senators were, including Texas Sen. Ted Cruz, chair of the Committee on Commerce, Science, and Transportation, which oversees NASA. Advisers in several GOP Senate offices involved in the nomination, including Cruz's, say they didn't know of any senators or staffers who opposed Isaacman. Cruz, indeed, raised objections in December, when Musk persuaded Trump to nominate Isaacman to lead NASA. Cruz raised two issues then: Isaacman had contributed to Democrats opposing GOP senators Tim Sheehy of Montana and Bernie Moreno of Ohio last year. Isaacman, like Musk, wants NASA to focus on colonizing Mars, but Cruz is focused on moon exploration. The Texas senator wants to compete with the Chinese space efforts there — and keep the Johnson Space Center in Houston operational as mission control for the Artemis program. Behind the scenes: Musk called Cruz when he heard of his objections. Isaacman then promised he would prioritize Artemis. Sheehy and Moreno said they had no problems with Isaacman. Cruz held a confirmation hearing on April 30 for Isaacman, whose nomination was approved by the committee 19-9. Three Senate sources and two White House insiders said they expected Isaacman to get 70 or 80 votes on the Senate floor, a rarity in the closely divided chamber. "I thought we were going to confirm him this week," Cruz told Axios. Asked if he had any input in scuttling Isaacman's confirmation, Cruz said: "That's not accurate." Meanwhile, Gor"spun up the president by just constantly mentioning the donations," a Trump adviser said. On May 30, before a joint press conference with Musk to announce his departure from the White House — which appeared amicable at the time — Gor dropped off a background file on Isaacman with Trump at the Oval Office. Musk later entered the room and Trump asked him about Isaacman. "This guy gave to Democrats," Trump said to Musk, according to a person familiar with the meeting. "It's not like Elon really defended him. He said, 'He's really competent. But yeah, he gave to Democrats,'" the source said.